Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for AlloSCT
NCT07565220Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of thiotepa in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (2 cohorts). Primary endpoint: GVHD-free, relapse-free survival at 1 year. Started Jul 2026; status: recruiting.
02
Drugs
thiotepa
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07565220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565220.